Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-001301

CHIEF OPERATING OFFICER sold 28,367 shares at an average $24.18 ($685,868)

  • CHIEF OPERATING OFFICER acquired 21,700 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Patel Anish · CHIEF OPERATING OFFICER

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2025-01-07 Exercise or conversion : show line 1 in the form 10b5-1 +10,700 $1.12 $11,984 10,700 D
2025-01-07 Exercise or conversion : show line 2 in the form 10b5-1 +2,000 $2.48 $4,960 12,700 D
2025-01-07 Exercise or conversion : show line 3 in the form 10b5-1 +9,000 $2.48 $22,320 21,700 D
2025-01-07 Sale : show line 4 in the form 10b5-1 −20,260 $24.15 $489,330 1,440 D
2025-01-07 Sale : show line 5 in the form 10b5-1 −1,440 $24.56 $35,368 0 D
2025-01-07 Sale : show line 6 in the form 10b5-1 −6,577 $24.17 $158,957 336,734 I
2025-01-07 Sale : show line 7 in the form 10b5-1 −90 $24.60 $2,214 336,644 I
Open-market sales · 28,367 sh · avg $24.18 · $685,868

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-01-07 Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) −10,700 67 D
2025-01-07 Exercise or conversion : show line 9 in the form 10b5-1 Employee Stock Option (right to buy) −2,000 827 D
2025-01-07 Exercise or conversion : show line 10 in the form 10b5-1 Employee Stock Option (right to buy) −9,000 44,342 D
Loading xslF345X05/form4-01102025_100148.xml…